- Q1 2024 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024€201.3 (-7.53%)Earnings
- Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Madrigal Pharmaceuticals Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call TranscriptJun 24, 2023
- Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptMay 16, 2023
- Madrigal Pharmaceuticals Inc to Announce Topline Data from the Phase 3 MAESTRO-NASH Study of Resmetirom Presentation TranscriptDec 19, 2022
- Madrigal Pharmaceuticals Inc EASL Investor Event Call TranscriptJun 25, 2022
- Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference TranscriptJun 14, 2022
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference TranscriptMay 24, 2022
- Q1 2022 Madrigal Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2022€54.5 (-10.66%)Earnings
- Madrigal Pharmaceuticals Inc Call to Discuss MAESTRO-NAFLD-1 Phase 3 Data TranscriptJan 31, 2022
- Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call TranscriptNov 16, 2021
- Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 10, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 19, 2020
Madrigal Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Hi. Good afternoon, everyone. Thank you so much for joining us here. I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Very happy to have Madrigal Pharmaceuticals here with us today. Joining us from Madrigal is the new CEO, Bill Sibold, Chief Executive Officer. Thank you so much for joining us during what appears to be a well-attended happy hour. I was told to now call this a fireside chat. And so with that, I'll turn it to you and ask what led to your decision to join Madrigal?
Well, Ellie, first of all, thanks for having me, having us here. It's a real pleasure to spend some time. Look, I'm 7 weeks into the new job. And I have to say, I've been waiting for that moment where I say, "Boy, is this the right thing to do?" And I can tell you, along the whole way, it's getting more and more exciting.
I think it's very rare in the industry to have an opportunity where there is a disease of such
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)